Some CFS researchers and patients have been taking the subject of oxidative stress and down-regulation of the glutathione very seriously for years now. I must admit, I was not one of them. Seemed a little too speculative, one of many imaginative theories out there, not clear evidence. But....maybe I was wrong. Looks like Biogen's next billion-dollar baby is a drug called BG-12. And guess what? It works by targeting oxidative stress's damaging effects on the neurons, and it positively effects the glutathione in the patient. This is the result of years of testing, many millions of dollars, and several laborious rounds of trials. Just read the first line in Biogen's release, then read the findings of CFS/ oxidative stress research. It's almost the same, word for word: http://www.ncbi.nlm.nih.gov/pubmed/22267202 The results from their phase III, study showed it to be quite beneficial in preventing relapses in MS patients. Many MS patients will tell you that it is not the ehancing lesions that are important in the treatment of this disease; it is finding a way of staving off the relapses. Because the relapses not only show neurological symptoms, but fatigue, intolerance to exercise, cognitive impairment also. Very similar to what we have. I was wondering if this is something Cort might ask our researchers about, as a possible new treatment modality. I would be very interest if they saw any parallels. We have seen possible off-label success with RTX so maybe this might work too.